Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series - Wikidata - awgldk - TriplyDB

Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series

Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series

http://www.wikidata.org/entity/Q35021812

about

Autoimmune Myopathies: Where Do We Stand?Treatment of inflammatory myopathy: emerging therapies and therapeutic targets Idiopathic inflammatory myopathies Rituximab in the treatment of inflammatory myopathies: a review Immunotherapies for Immune-Mediated Myopathies: A Current Perspective Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies.Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy.Idiopathic inflammatory myopathies.Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.An overview of polymyositis and dermatomyositis.Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients.Anti-signal recognition particle autoantibody ELISA validation and clinical associations.Diagnosis and treatment of the idiopathic inflammatory myopathies Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Physical Dysfunction after Treatment in Polymyositis and Dermatomyositis: An Observational Study of Physical Dysfunction with Myositis in Japan Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics.A 64-Year-Old Woman with Chest Pain, Limb Weakness, and Endometrial Cancer.Therapeutic approaches in myositis.Targeted immunotherapy trials for idiopathic inflammatory myopathies.Myositis autoantibodies.Review: immune-mediated necrotizing myopathies--a heterogeneous group of diseases with specific myopathological features.Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature.Novel antibody associations in immune-mediated necrotising myopathy without inflammation.The Clinical Features of Myositis-Associated Autoantibodies: a Review.Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management.Treatment of Juvenile Dermatomyositis: An Update.Current pharmacological treatment of idiopathic inflammatory myopathies.Immune-mediated necrotizing myopathy.Update on the pharmacological treatment of adult myositis.Autoimmune Myopathies.Immune-mediated necrotizing myopathy, associated with antibodies to signal recognition particle, together with lupus nephritis: case presentation and management.Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle.Heterogeneous clinical spectrum of anti-SRP myositis and importance of the methods of detection of anti-SRP autoantibodies: a multicentric study.Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis.High-dose cyclophosphamide without stem cell rescue in immune-mediated necrotizing myopathies.Novel approaches in the treatment of myositis and myopathies.Immune-mediated necrotising myopathy associated with antibodies to the signal recognition particle treated with a combination of rituximab and cyclophosphamide.Successful treatment of refractory anti-signal recognition particle myopathy using abatacept.Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity.Childhood autoimmune necrotizing myopathy with anti-signal recognition particle antibodies.Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy.

P2860

Q26744554-8F23CC7A-63C6-4CDD-8E45-3C06519FADD6 Q26796546-7DC49E41-091C-4A04-872F-4916DB272AEF Q27025125-00E80C09-3B0A-4DEC-8361-6500902C4149 Q28077745-9DB74601-C509-4E91-B2E0-BE4159E3E36A Q30699742-4A796F51-3D44-49BD-89A7-83D30D6B1A45 Q33717793-17BA7AF9-3F77-4839-88D3-C77EAE248C60 Q33844947-D3111125-2D69-47E8-8E40-7F2429CC45AD Q33924451-053D0AC5-E90B-429E-955A-BE7F409CBF62 Q34644962-1BAA4B9D-86EB-444D-90B0-C0027CBA7546 Q34667765-D76A9EE5-3396-45B0-91F0-616B6B2C72A7 Q35632755-AB9E1845-B347-4DED-BBD5-DFCB32E708D4 Q35759167-AF60E6E6-8335-49F1-ADD8-FE21BFFC043A Q36059440-22C087B5-3AD4-418C-B51A-1667AAEC8496 Q36559044-31AC8D02-17FF-429A-A175-6BDBAC711499 Q37095730-F077B10A-14F1-4C38-BA46-A437AA0CE5D5 Q37714668-BD0DEE1B-127C-46B2-8A7F-6705EF640CEA Q37848694-9A6E7A87-33E9-4969-A4E6-09CA63CA90A0 Q38023207-E9CB5F31-F223-4C3A-B527-FAB0ED9E72CF Q38041385-D87C9FA4-D444-4469-A98B-D5B86CBB1880 Q38044467-831DB15E-6CCF-45C2-B0CF-F853F7D44504 Q38097748-73AA9CE1-2CC7-4E70-8A54-17780A5643AC Q38264055-C8732A76-BD04-4E4C-B178-AA3F35DDF341 Q38603422-BDEC0BC9-950C-481C-A6C0-88ACF75F7064 Q38619882-302D025C-2C01-4F86-B574-5BD7AEA74154 Q38678257-D8F67CE0-2EA1-4796-BCD9-000A9856FF84 Q38680762-986F29C2-69B9-4A3A-9B68-3F78A9330AC8 Q38702361-D76D9942-8BE8-469D-B5AD-4D89C2273E71 Q38813275-6B23BD96-30AC-4817-BBB3-B7CEEDB2D627 Q39030495-856215E6-A2CA-4560-91CA-0CA27FADA759 Q39570030-334C048F-2CAB-4BCE-84E5-8928E4C90B94 Q39824090-428F6F6A-1DD6-482B-B693-58CEC9722223 Q40130278-3F2C8598-4B6A-4BC4-B669-3B62CB985BBC Q40747808-FB05A7D8-8087-4FA8-9549-CF65E7E7012D Q41814408-E2700F8A-2FA2-4AF8-A0E7-02CBE74E1A78 Q41977818-B2BAB6E1-3C93-4421-922E-43D1880DA225 Q42450910-CB2F84EA-3803-4C0C-9CFD-9F422B755837 Q45930377-C5E9D862-6D30-4687-8789-F1260E21BF79 Q48344148-E33C33EB-FE39-4E91-B384-4AC099474939 Q51199320-2EAE0676-8A2B-4C60-9C48-AA4C25526077 Q51527887-74957C6B-BC61-4401-B45E-B2BB943DB49C

P2860

Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series

http://www.wikidata.org/entity/Q35021812

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Rituximab therapy for myopathy ...... icle antibodies: a case series

@ast

Rituximab therapy for myopathy ...... icle antibodies: a case series

@en

type

label

Rituximab therapy for myopathy ...... icle antibodies: a case series

@ast

Rituximab therapy for myopathy ...... icle antibodies: a case series

@en

prefLabel

Rituximab therapy for myopathy ...... icle antibodies: a case series

@ast

Rituximab therapy for myopathy ...... icle antibodies: a case series

@en

P1433

Q35021812-6C69C25D-5B9E-49BC-8599-FD22FE1ED134

P1476

Q35021812-284B425D-B878-40C8-BE65-F88014F2CA4A

P2093

Q35021812-30FA035F-CF07-4B55-AF85-BE28304DB8D9

Q35021812-83B0AD37-D450-42D2-A664-837391EC2F35

Q35021812-8DE788E3-1274-44EF-AF34-047D56EC363F

Q35021812-91269FB4-DD9E-4CE7-B1C8-22ECB313697B

Q35021812-9F969B97-344C-47AD-814E-0E054DBE28EE

P2860

Q35021812-0EF8408A-A1DB-4439-996B-6DC7DA7F4696

Q35021812-153503D5-4E6A-48F0-BADF-9D5753901A2B

Q35021812-1B10C381-5159-4979-B01E-885715A7EA75

Q35021812-1DDFF21B-FC52-4361-8CD5-3F78ECA2656A

Q35021812-20F0F3C8-E83F-4D28-A18B-4F6DD0619888

Q35021812-22CA2191-B4D3-47AB-BB8B-6A5527D9DD14

Q35021812-5EA174E4-C174-40FC-8F8D-53D4DCEE785D

Q35021812-705890E9-1EF3-40C2-8579-A9016947C616

Q35021812-735ECFFE-A421-4CFC-B952-926AAAB7B9A6

Q35021812-92D64433-03D0-4BCC-9DFA-BE3811E56F40

P304

Q35021812-04CAB96F-7D06-4FF9-A43A-17B59D45449A

P31

Q35021812-2E8BA8D5-A19C-44C9-9418-BEAA33ED1FE1

P356

Q35021812-CA8DA818-F1E3-49A8-AE5B-A362571BA819

P433

Q35021812-7CA47855-F54B-48DB-8C56-DF8A1005CFCE

P478

Q35021812-F44C05C3-113A-4682-9FB7-8E42F340CBE6

P577

Q35021812-54B4BED2-FF93-45F3-BCCB-8492E2FE2BBE

P5875

Q35021812-1F93AE65-FDCD-41A1-AC01-2B018DBC1F12

P698

Q35021812-4022A609-72E5-4C6A-B1FA-AF4048ED381F

P921

Q35021812-52BB53CE-8D38-4A47-998C-1489E5AB78F9

P932

Q35021812-26FFF6DD-0419-46B5-B31C-0C15423921FE

P356

P1433

Arthritis Care and Research

P1476

Rituximab therapy for myopathy ...... icle antibodies: a case series

@en

P2093

Andrew Mammen

http://www.w3.org/2001/XMLSchema#string

Grace Hong

http://www.w3.org/2001/XMLSchema#string

Lisa Christopher-Stine

http://www.w3.org/2001/XMLSchema#string

Livia Casciola-Rosen

http://www.w3.org/2001/XMLSchema#string

Ritu Valiyil

http://www.w3.org/2001/XMLSchema#string

P2860

Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.

Polymyositis and dermatomyositis (first of two parts).

Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy.

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.

Myopathy with antibodies to the signal recognition particle: clinical and pathological features.

Autoantibody profiles in the sera of European patients with myositis.

Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy.

Contribution of autoantibodies to the diagnosis and nosology of inflammatory muscle disease.

Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy.

P304

1328-1334

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ACR.20219

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44634133

http://www.w3.org/2001/XMLSchema#string

P698

20506493

http://www.w3.org/2001/XMLSchema#string

P921

P932

3107255

http://www.w3.org/2001/XMLSchema#string